Variety of qualified sufferers: CDEC reviewed the uncertainty in the volume of people with reasonably intense to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific specialists consulted by CADTH indicated that some people who will be categorised as owning moderate or reasonable sickness might have a severe bleeding phe